Lisanti Capital Growth, LLC Biocryst Pharmaceuticals Inc Transaction History

Lisanti Capital Growth, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 01, 2022	BUY	$10.79 - $14.81 $3.29 Million - $4.52 Million	305,095 New	305,095 $3.84 Million
Q2 2022 Aug 03, 2022	SELL	$7.89 - $17.88 $5.23 Million - $11.8 Million	-662,644 Closed	0 $0
Q1 2022 May 12, 2022	BUY	$11.56 - $19.76 $7.66 Million - $13.1 Million	662,644 New	662,644 $10.8 Million
Q4 2021 Feb 04, 2022	SELL	$11.18 - $15.46 $2.45 Million - $3.39 Million	-219,450 Closed	0 $0
Q3 2021 Nov 03, 2021	SELL	$14.21 - $17.65 $1.74 Million - $2.17 Million	-122,735 Reduced 35.87%	219,450 $3.15 Million
Q2 2021 Aug 16, 2021	SELL	$9.5 - $17.24 $1.24 Million - $2.25 Million	-130,335 Reduced 27.58%	342,185 $5.41 Million
Q1 2021 May 12, 2021	BUY	$7.37 - $13.61 $3.48 Million - $6.43 Million	472,520 New	472,520 $4.81 Million
Q2 2019 Aug 05, 2019	SELL	$2.91 - $9.15 $644,754 - $2.03 Million	-221,565 Closed	0 $0
Q1 2019 May 13, 2019	BUY	$7.38 - $9.72 $1.64 Million - $2.15 Million	221,565 New	221,565 $1.8 Million

278

172M

625K

739K

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.41B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

Get notified when there are updates to the investment portfolio of Lisanti Capital Growth, LLC, based on Form 13F filings with the SEC.

Stay updated on Lisanti Capital Growth, LLC with notifications on news.